Apoc II Mimetic Peptides Patent Application
Summary
The European Patent Office published patent application EP3571216A1 for Apoc II mimetic peptides. Co-applicants are the United States Department of Health and Human Services and Novo Nordisk A/S. The application covers peptide compositions for therapeutic use in cardiovascular and metabolic conditions.
What changed
The EPO published patent application EP3571216A1 on March 25, 2026, for Apoc II mimetic peptides with co-applicants the United States Department of Health and Human Services and Novo Nordisk A/S. The application is classified under C07K 14/00, C07K 14/435, and A61K 38/00 and designates all EPC contracting states.
This is a patent publication notice with no immediate compliance obligations for third parties. Pharmaceutical companies developing cardiovascular or metabolic therapies should monitor this application for potential freedom-to-operate implications. The patent, once granted, will provide exclusivity rights in the designated European states.
Source document (simplified)
APOC-II MIMETIC PEPTIDES
Publication EP3571216A1 Kind: A1 Mar 25, 2026
Applicants
The United States of America, as represented by
the Secretary, Department of Health and
Human Services, NOVO NORDISK A/S
Inventors
REMALEY, Alan, Thomas, GHOSH, Soumitra, Shanker, DEVALARAJA, Madhav, N., LO, Chih-Hung, SVIRIDOV, Denis, O., WOLSKA, Anna
IPC Classifications
C07K 14/00 20060101AFI20200928BHEP C07K 14/435 20060101ALI20200928BHEP A61K 38/00 20060101ALI20200928BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Named provisions
Related changes
Source
Classification
Who this affects
Taxonomy
Browse Categories
Get Pharma & Drug Safety alerts
Weekly digest. AI-summarized, no noise.
Free. Unsubscribe anytime.
Get alerts for this source
We'll email you when ChangeBridge: EPO Bulletin - Pharma (A61K) publishes new changes.